In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Changes in the quality of life in patients with stable coronary artery disease after coronary artery bypass grafting or stenting at 6-month follow-up

Session Poster Session 1

Speaker Yuliia Borkhalenko

Congress : Acute Cardiovascular Care 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention
  • Session type : Poster Session
  • FP Number : P279

Authors : Y Borkhalenko (Kyiv,UA), O Zharinov (Kiev,UA), B Todurov (Kyiv,UA), 0 Yepanchintseva (Kyiv,UA)

Authors:
Y Borkhalenko1 , O Zharinov2 , B Todurov1 , 0 Yepanchintseva1 , 1Heart Institute of the Ministry of Healthcare of Ukraine - Kiev - Ukraine , 2Shupyk Natoinal Medical Academy of Postgraduate Education - Kiev - Ukraine ,

Citation:

Background. Coronary artery bypass grafting (CABG) in patients with stable coronary artery disease (CAD) and preserved left ventricular (LV) ejection fraction (EF) is mainly performed to decrease angina and improve quality of life (QOL). The parameters of QOL may be related to LV diastolic dysfunction.

Purpose: to evaluate QOL, LV diastolic function parameters and brain natriuretic peptide (BNP) in patients with CAD and preserved or mid-range LVEF before and 6 months after CABG.

Methods. The cross-sectional single-center retrospective study included data from clinical and instrumental examination of 71 patients with CAD and preserved or mid-range systolic function (LVEF =40%), consecutively selected for CABG. Among them, there were 60 men and 11 women aged 57 to 70 years, middle age (64±4) years. 11 (17%) patients had signs of stable angina ?I functional class (FC), 44 (69%) had III FC, 9 (14%) – IV FC. We analyzed FC of angina, QOL parameters by  using SF-36, Seattle Angina Questionnaire (SAQ), the Minnesota Living with Heart Failure Questionnaire (MLHFQ), the echocardiographic parameters and the BNP level before and 6 months after CABG.

Results. Six months after CABG a significant improvement of QOL was registered by questionnaires MLHFQ, SF-36 and SAQ, compared to baseline (p <0,001), including the scales of the frequency of angina attacks, physical and emotional functioning, mental health and manifestations of heart failure. The angina symptoms significantly decreased: there were no angina attacks in 38 (59%) patients, and I and II FC were observed in 25 (39%) patients (p <0,001). Reduced FC by 2 or more grades was registered in 45 (70%) patients after CABG. Six months  after surgery, there was a significant improvement in LV diastolic function, namely reduction of DT from median 262 (quartiles 223-296) ms to 250 (220-280) ms (p <0,001), IVRT from 118 (109-125) ms to 112 (105-115) ms (p = 0,021), and increase of E/A from 0,82 (0,73-0,93) to 0,92 (0,76-0,99) ( p = 0,043). The BNP level decreased from 115,4 (62,0-150,6) pg/ml to 52,4 (20,4-95,9)  pg/ml (p <0,001).

Conclusion. Reducing angina pectoris and improving parameters of QOL 6 months after CABG is associated with positive changes of LV diastolic function parameters and decrease of BNP.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are